Gainers

• Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million.
• Definium Therapeutics (NASDAQ:DFTX) stock increased by 17.69% to $48.15. The market value of their outstanding shares is at $5.4 billion. The company's, Q2 earnings came out 4 days ago.
• Dermata Therapeutics (NASDAQ:DRMA) stock increased by 17.59% to $1.27. The company's market cap stands at $4.3 million. As per the press release, Q2 earnings came out yesterday.
• Apyx Medical (NASDAQ:APYX) shares moved upwards by 14.27% to $3.45. The company's market cap stands at $127.2 million. As per the press release, Q2 earnings came out 4 days ago.
• TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 13.7% to $3.9. The market value of their outstanding shares is at $3.6 million.
• Innate Pharma (NASDAQ:IPHA) shares rose 12.55% to $2.42. The market value of their outstanding shares is at $201.7 million.

Losers

• Silexion Therapeutics (NASDAQ:SLXN) stock decreased by 58.0% to $0.43 during Wednesday's pre-market session. The company's market cap stands at $1.1 million.
• Edap TMS (NASDAQ:FOCL) shares declined by 20.97% to $4.75. The market value of their outstanding shares is at $225.2 million.
• SILO Pharma (NASDAQ:SILO) stock fell 19.67% to $2.86. The market value of their outstanding shares is at $4.0 million.
• Concord Medical Services (NYSE:CCM) stock decreased by 15.06% to $4.4. The market value of their outstanding shares is at $22.4 million.
• Cryo-Cell International (AMEX:CCEL) shares declined by 14.53% to $3.0. The company's market cap stands at $28.2 million.
• Milestone Pharmaceuticals (NASDAQ:MIST) shares declined by 11.82% to $1.12. The company's market cap stands at $158.1 million. The company's, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.